Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial
1. Radiation Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain;2. Statistics Department, University of Salamanca, Salamanca, Spain